chief-business-officer
(57)
Shruthi Rao
Shruthi Rao is the co-founder of Vendia, a San Francisco multi-cloud distributed data platform that helps enterprises share and reconcile data in real time across companies, clouds, and tech stacks. Before Vendia she founded the blockchain practice at AWS, launching Amazon Managed Blockchain and Amazon Quantum Ledger Database, and led business development for the AWS serverless portfolio including Lambda and API Gateway. She set up what she describes as India's first crypto mining operation in 2011 and has advised the Ethereum Project, Ripple, MOBI, the Linux Foundation, and the World Economic Forum.
Brendan Dowdle
Brendan Dowdle is the Chief Business Officer of Bonsai Robotics, a Silicon Valley company building vision-based autonomy software for agriculture. He arrived there in 2025 when Bonsai acquired farm-ng, the modular farm-robot maker he ran as CEO. Dowdle grew up in an agricultural family across Southeast Asia, watched his agronomist father work the ground, and spent a decade building computer-vision and robotics companies before turning that toolkit on farming. He co-founded Arraiy (acquired by Matterport, where he later helped scale the services business through IPO), holds an MBA from Stanford, and now argues that the future of farming will be driven by intelligence, not iron.
Kam Eshghi
Kam Eshghi is Chief Business Officer at OpenInfer, the Inference OS for the agentic era. He co-founded Lightbits Labs, where he helped pioneer NVMe/TCP storage and drove its adoption across data centers and AI clouds before the company was acquired by NVIDIA. Earlier in his career he led strategic alliances at DSSD (acquired by EMC for $1B), built the NVMe controller business at IDT, and shaped server chipset and Ethernet switch roadmaps at Intel. MIT EECS and Berkeley Haas MBA. Forbes Technology Council member.
Andrew DeSomma
Andrew DeSomma is the Chief Business Officer of K2bio (K2 BioLabs), a Houston-based hybrid contract research organization that gives early-stage life-science companies the equipment, vivarium, and scientists they could never afford to build alone. A career investor with a 25-plus-year track record across technology, biotech, consumer, and retail, he is the founder and manager of Resolute Investments and previously analyzed companies for crossover hedge funds in the San Francisco Bay Area. A Georgetown graduate who now works from Santa Fe, he sat on K2's board at founding before stepping into the operating seat that turns the lab's science into deals.
Angèle Maki
Angèle Maki, PhD, is a biopharmaceutical business development executive with more than 20 years of deal-making across emerging biotechs and global pharma. In December 2025 she became the first Chief Business Officer of Ability Biotherapeutics, a Montreal-based company building logic-gated antibodies with its generative-AI platform AbiLeap. A Stanford-trained biological chemist who started at the University of Winnipeg, she has held senior roles at Medarex, Bristol Myers Squibb, Genentech, 23andMe, Merck, Eli Lilly, ReCode Therapeutics and Callio Therapeutics, and chairs the non-profit Canadian Entrepreneurs in Life Sciences.
Hiranjith H
Hiranjith H (also Hiranjith GH) is the Chief Business Officer of Algorithmic Biologics, a Bengaluru-founded deeptech startup that embeds algorithms inside test tubes to make molecular testing dramatically cheaper and faster. Based in the San Francisco Bay Area, he leads the company's commercial operations and US expansion. He spent more than a decade scaling MedGenome's research-services business in the US and earlier built commercialization and analytics strategy for life-sciences clients at Novartis, ZS Associates, and Accenture Management Consulting.
Matt Stone
Matt Stone is the Chief Business Officer of Corvic AI, the Mountain View startup building an Intelligence Composition Platform that sits between raw enterprise data and production AI. A Stanford-trained engineer who once walked on as a quarterback at the University of Arizona, Stone has spent more than a decade turning hard enterprise technology into revenue - first at Boeing, then as an operating partner at Intel Capital, and most recently leading strategic partnerships at the cybersecurity firm SecurityScorecard. He joined Corvic AI in March 2026 to scale its enterprise go-to-market across pharma, manufacturing, and logistics.
Nate Beyor
Nate Beyor is Chief Business Officer at Salt AI, the Los Angeles contextual-AI platform built for life sciences and healthcare. A bioengineer turned consultant turned operator, he holds a PhD in bioengineering from UC Berkeley, where he built microfluidic devices to detect pathogens. He spent his career at the seam between technology and biology - microfluidics, biologics manufacturing, stem cell therapy at Asterias Biotherapeutics, and digital health - before leading the Health Tech practice as a Managing Director and Partner at Boston Consulting Group. At Salt AI he runs corporate strategy, the solutions portfolio, and market expansion, helping translational scientists and drug developers move faster with AI they can actually trust in regulated settings.
Ramon Salsas Escat
Ramon Salsas Escat is the Chief Business Officer of GEMMA Biotherapeutics (GemmaBio), the Philadelphia gene-therapy company spun out of Jim Wilson's lab to widen global access to AAV therapies for rare inherited diseases. A chemist by training who earned a PhD in computational and systems biology at MIT and an MBA at IESE, Salsas has led or co-led more than 20 transactions across AAV gene therapies, CNS disorders, oncology and manufacturing platforms, with cumulative deal value north of $4 billion in upfront payments and milestones. He helped build the business engine at Penn's Gene Therapy Program, served as SVP of Business Development at G2 Bio, and now runs business development, alliance management, legal and IP at GemmaBio, where he played a pivotal role in the company's founding and its $34 million seed round.
Rohan Pavuluri
Rohan Pavuluri is the Chief Business Officer at Speechify, the consumer voice-AI app, and the co-founder of Upsolve, the nonprofit whose free online tool has helped low-income Americans erase hundreds of millions of dollars in debt through bankruptcy. A Harvard statistics graduate and Phillips Exeter alum, he built Upsolve out of a Harvard Law access-to-justice lab as an undergraduate, led it as CEO until 2022, and now serves as its volunteer board chair. He is a TED Fellow, a TIME100 Next honoree, and a Forbes 30 Under 30 recognized for arguing that civil rights should be free.
Scott Peterson
Scott Peterson is the Chief Business Officer of T-Cypher Bio, an Oxford-based biotech building next-generation TCR therapeutics for solid tumors and autoimmune disease. A Harvard-trained PhD who started his career at the lab bench as a medicinal chemist at Merck, he crossed over to the deal side and spent two decades shaping pipelines and partnerships at Intarcia, Spero, and Dewpoint Therapeutics before taking the commercial helm at T-Cypher. He is the rare dealmaker who can read both a term sheet and a reaction mechanism.
Scott Greenberg
Scott Greenberg is the Chief Business Officer of Nura Bio, a clinical-stage biopharmaceutical company in South San Francisco building small-molecule drugs to stop nerves from dying. He joined in February 2025 to steer business development and corporate strategy as the company pushes its lead SARM1 inhibitor, NB-4746, into the clinic. He arrives with more than two decades crossing the line between finance and biology - a Goldman Sachs banking start, more than a decade at Celgene, an operations leadership role at Roivant Sciences, and a stint as Chief Operating Officer at Aro Biotherapeutics. He studied both Finance and the Biological Basis of Behavior at the University of Pennsylvania before an MBA at Harvard.
Aditya Venugopal
Aditya Venugopal is the Chief Business Officer of Alentis Therapeutics, a clinical-stage Swiss biotech chasing first-in-class therapies aimed at claudin-1 for fibrosis and cancer. An immunologist turned dealmaker, he spent 15-plus years moving between the lab bench and the negotiating table: a Ph.D. in immunology from Weill Cornell, seven years in strategic life-science consulting, then senior roles at Intercept, VectivBio and Versanis Bio. He has a habit of being in the room when companies get acquired - VectivBio went to Ironwood, Versanis went to Eli Lilly - and he reunited with CEO Mark Pruzanski at Alentis after first partnering with him at Intercept.
Alastair Blake
Alastair Blake is the Chief Business Officer of Layer Health, an MIT-spinout building an AI layer for clinical chart review backed by Google Ventures, General Catalyst and Define Ventures. A Cambridge-trained physician (MD, MRCP) turned commercial operator, he trained as an internal medicine doctor in the NHS, served a National Medical Director's Clinical Fellowship at the Care Quality Commission, earned an MBA from Wharton, consulted at McKinsey, and led clinical and commercial partnerships at the healthcare data company nference before joining Layer Health in 2024. He sits at the intersection of medicine, data and go-to-market - a doctor who now sells the software meant to give doctors their time back.
Andy Hu
Andy Hu is a physician-turned-dealmaker who serves as Chief Business Officer of Augustine Therapeutics, a Leuven and Cambridge biotech advancing next-generation selective HDAC6 inhibitors for neuromuscular, neurodegenerative, and cardio-metabolic diseases. He joined permanently in April 2025 after a stint as advisor, fresh off serving as CBO of Arkuda Therapeutics through its acquisition by Johnson & Johnson. Trained as an MD at Baylor with an MBA from Rice and an undergraduate degree from Harvard, Hu has built a career steering life sciences companies through IPOs, partnerships, and acquisitions - from Dimension Therapeutics to Ultragenyx, plus stints in investment banking at Leerink Partners and consulting at Strategic Decisions Group.
Brian Brown
Brian Brown is the Chief Business Officer of Brave Software, the privacy-first browser company founded by JavaScript creator Brendan Eich. Since 2016 he has led the business side of Brave's bet to rewire online advertising around consent and the Basic Attention Token (BAT), pitching publishers, brands, and platforms on a model where users get paid for their attention. A veteran startup operator, he co-founded and helped run cloud-computing pioneer Joyent (later acquired by Samsung), founded enterprise and software startups before that, and began his career in journalism and human rights work. He is a Vassar graduate and a marathon runner who likes to quote Aristotle when people ask him about success.
Brian Hotchkiss
Brian Hotchkiss is the Chief Business Officer of Bexorg, a Yale University spinout building the first integrated AI and whole-human-brain platform for central nervous system drug discovery. A chemical engineer turned biotech dealmaker, he spent nearly seven years at Stealth BioTherapeutics shaping corporate strategy and helping land a transformative Alexion collaboration, then served as Chief Business Officer at Protego Biopharma before joining Bexorg. He pairs four graduate-level degrees in engineering, biology, and business with a career spent translating hard science into partnerships, capital, and commercial strategy.
Colin McGlynn
Colin McGlynn is the Chief Business Officer at Copado, the intelligent DevOps platform built for Salesforce and low-code enterprise development. He runs the commercial engine of a company that raised $140M in Series C funding and crossed a valuation north of $400M. A Dartmouth economics and classical archaeology grad with a Yale MBA, he built his operator's instinct across BCG, Gartner, Business Intelligence Advisors, Uplift, and Own Company, where he overhauled go-to-market for a $150M+ ARR business before taking the reins of Copado's business strategy.
Colin South
Colin South is a New Zealand-born biotechnology executive and the founding leader of ArkeaBio, a Boston climate-tech company building the world's first vaccine to cut methane emissions from cattle. He grew up on a 1,000-head sheep farm, earned a PhD in bioprocess engineering from Dartmouth, and spent 25-plus years turning microbes into commercial products across the food, fuel, and energy industries. He launched ArkeaBio in 2021, ran it as CEO from January 2022, and in September 2025 stepped into the Chief Business Officer seat as the company brought in a new CEO and pushed toward field trials.
David Block-Schachter
David Block-Schachter is the Chief Business Officer at Transit, the multimodal trip-planning and fare-payment app used in cities across North America and Europe. A car-free MIT transportation PhD who started his career designing websites for American Express and IBM, he co-founded the microtransit startup Bridj, ran customer technology as CTO of the MBTA, and now helps transit agencies turn rider data into faster buses and simpler fares. His through-line: use technology and data to make public transit work better for everyone.
David Hendren
David Hendren is the Chief Business Officer of QURA, Inc., a Massachusetts medical technology company building an implantable sensor that streams real-time blood-pressure data to patients and physicians. A lawyer by training who has spent more than 25 years working every side of the deal table - venture capitalist, entrepreneur, CEO, board chair, advisor and counsel - he co-founded QURA in 2013 alongside its CEO. He also runs the advisory firm Augmentum Advisors, mentors startups through MassChallenge, sits on a Massachusetts Life Sciences Center review board, and advises VIC Technology Ventures, focusing his career on financing and commercializing healthcare and biomedical innovation.
David Matthews
David Matthews, PhD, is Chief Business Officer at Beacon Biosignals, the computational neurodiagnostics company turning EEG brain data into AI-powered biomarkers for neurological and psychiatric disease. A computational neuroscientist by training, he spent two decades moving between the lab, the boardroom, and the market - from NIH- and NSF-funded research at the Salk Institute to a partnership at Boston Consulting Group to commercial leadership at digital-health platform BrightInsight. He now drives partnerships and commercial growth at a company betting that the brain can be measured at home, at scale.
David Steinberg
David Steinberg is Chief Business Officer at Formation Bio, an AI-native pharmaceutical company in New York, where he runs in- and out-licensing and pipeline strategy. A serial biotech company builder, he co-founded PureTech Health and served as its Chief Innovation Officer, was a General Partner at Longwood Fund, and founded or led a string of NASDAQ-listed and venture-backed companies including Pyxis Oncology, Vor Biopharma, Vedanta Biosciences and Be Biopharma. He pairs a Cornell biology degree with a University of Chicago Booth MBA and a career that began in R&D and strategy consulting.
David Stoffel
David Stoffel is the Chief Business Officer of RapidAI, the clinical-AI company whose stroke-imaging algorithms helped rewrite the rules of how strokes get treated. A medical doctor who chose boardrooms over bedsides, he has spent more than two decades turning ambitious medical technologies into standards of care - from the da Vinci surgical robot at Intuitive Surgical to mobile cardiac telemetry at iRhythm and point-of-care EEG at Ceribell. At RapidAI he runs the commercial engine: marketing, clinical affairs, education, customer success, corporate development, and finance.
Evan Gibson
Evan Gibson is the Chief Business Officer of Sensorium Therapeutics, a Boston-based, clinical-stage biotech using its AI-driven SensAI platform to turn nature's neuroactive chemistry into precision treatments for brain and mental health. A Wharton-trained dealmaker, he has spent his career on the business side of central-nervous-system biotech - building partnerships, strategy and corporate development across a string of neuroscience and therapeutics ventures including Neumora, Tempero Bio, Junevity, Aditum Bio and Vir Biotechnology.
Han Lim
Han Lim is the Chief Business Officer of DeepCure, a Boston-based company building an end-to-end automated platform for small molecule drug discovery that pairs AI with a virtual library of a quintillion synthesizable compounds, robotic synthesis, and automated assays. A physician-scientist by training, he holds a medical degree from the University of Queensland, a PhD from the University of Cambridge, and did postdoctoral physics research at MIT before spending roughly a decade on the UC Berkeley faculty running a lab in systems biology and bioengineering. He helped build the first generation of AI drug discovery companies as Chief Business Officer at Atomwise, where he launched the internal pipeline, raised $168M across two rounds, and signed partners including Eli Lilly and Charles River Laboratories. He now leads business development, portfolio planning, and corporate strategy at DeepCure.
Jennifer Bergheiser
Jennifer Bergheiser is the Chief Business Officer of eGenesis, the Cambridge biotech turning gene-edited pig organs into a real answer to the transplant waitlist. She runs corporate strategy and all portfolio and commercial development, drawing on more than two decades across big pharma, venture capital, and consulting. Her resume runs from screening deals at Domain Associates to steering the blockbuster autoimmune drug Stelara at Centocor/Johnson & Johnson. At eGenesis she helps commercialize one of medicine's boldest bets: organs grown in pigs, edited dozens of times over, transplanted into living humans.
Kimberly Nearing
Kimberly Nearing is the Chief Business Officer of MaveriX Oncology, a Palo Alto biotech building tumor-selective small molecule drug conjugates. She is a Venture Partner at BVCF (Bioveda China Fund) and spent over a decade as Managing Director and Head of Life Sciences at the Hong Kong-based Cedrus Group, building bridges for capital and deals between the U.S., Europe, and Greater China. With early operating years at Amgen, Merck, and IBM Healthcare and a master's from Harvard, she pairs deep biotech operating experience with the relationships that move money across the Pacific.
Kurt Tsuo
Kurt Tsuo is the Chief Business Officer of Varaha, a Gurugram-based carbon removal company building high-integrity credits with smallholder farmers across Asia and Africa. A Harvard-trained economist who spent seven years in agriculture before it was a climate headline, he has built business lines at the Gates Foundation, Farmer's Business Network, ProducePay, and Breakthrough Energy, and co-founded the carbon storage startup Graphyte. His through-line is unglamorous and stubborn: make the economics of fixing carbon work for the people who actually grow food.
Leah Cohen-Shohet
Leah Cohen-Shohet is co-founder and Chief Business Officer of GlossGenius, the all-in-one booking, payments, and point-of-sale platform built for beauty and wellness professionals. A Princeton economics graduate and former Goldman Sachs strategic investor, she left a fintech career at Symphony and Archipelago to scale the company her twin sister Danielle founded out of a Princeton dorm-room makeup side hustle. Under their partnership GlossGenius has grown to serve tens of thousands of independent beauty businesses, reached a valuation north of half a billion dollars, and raised roughly $134 million in total funding.